Tracers / [18F]pi2620

[18F]pi2620

Also written as [18F]PI-2620; [18F]PI2620; [F-18]PI-2620; [F-18]PI2620; F-18 PI-2620; PI-2620
Radionuclide
F-18 t½ 109.77 min
Modality
PET
Production route
—
Stage
—
Syntheses indexed
0
Alzheimer's diseaseDementia other than Alzheimer'sParkinsonian syndromes and movement disordersTau pathologyHuntington's diseaseSubstance use disorders / addiction

What it is

Compound class
—
Target / mechanism
Tau aggregates (second-generation tau PET tracer, including 4R tauopathy tau) PMID 42463287
Clinical application
Cognitively unimpaired older adults at risk for Alzheimer's disease PMID 42463287
Theranostic pair
—

Regulatory status

FDA
—
EMA (centralised)
—
Other approvals
—
Brand names
—

Clinical use

Typical injected activity
—
Uptake time
—

Reported in the literature. Not a dosing recommendation.

Published syntheses

No synthesis has been parsed for this agent yet.

Need this precursor?We can point you to suppliers for [18F]pi2620, or handle the enquiry for you.

Get in touch

Quality control Preliminary — inferred from compound class

Ph. Eur. monograph
—
USP monograph
—
AppearancepHRCP HPLCRCP TLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrity
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [18F]pi2620.

Get in touch

Notes

Added from reverse module search (stage 6); 3 article(s) with F-18. | Stage 28: added indication(s) neu-huntington, psy-addiction from consolidated missing-rubric review.